Format
Sort by
Items per page

Send to

Choose Destination

Best matches for oncolytic herpes simplex:

Search results

Items: 1 to 20 of 694

1.

Enhanced Sensitivity of Patient-Derived Pediatric High-Grade Brain Tumor Xenografts to Oncolytic HSV-1 Virotherapy Correlates with Nectin-1 Expression.

Friedman GK, Bernstock JD, Chen D, Nan L, Moore BP, Kelly VM, Youngblood SL, Langford CP, Han X, Ring EK, Beierle EA, Gillespie GY, Markert JM.

Sci Rep. 2018 Sep 17;8(1):13930. doi: 10.1038/s41598-018-32353-x.

2.

Pharmacy Operationalization of the Intralesional Oncolytic Immunotherapy Talimogene Laherparepvec.

McBride A, Valgus J, Parsad S, Sommermann EM, Nunan R.

Hosp Pharm. 2018 Oct;53(5):296-302. doi: 10.1177/0018578717749926. Epub 2018 Jan 10.

PMID:
30210146
3.

Active-site mTOR inhibitors augment HSV1-dICP0 infection in cancer cells via dysregulated eIF4E/4E-BP axis.

Zakaria C, Sean P, Hoang HD, Leroux LP, Watson M, Workenhe ST, Hearnden J, Pearl D, Truong VT, Robichaud N, Yanagiya A, Tahmasebi S, Jafarnejad SM, Jia JJ, Pelin A, Diallo JS, Le Boeuf F, Bell JC, Mossman KL, Graber TE, Jaramillo M, Sonenberg N, Alain T.

PLoS Pathog. 2018 Aug 23;14(8):e1007264. doi: 10.1371/journal.ppat.1007264. eCollection 2018 Aug.

4.

A fully-virulent retargeted oncolytic HSV armed with IL-12 elicits local immunity and vaccine therapy towards distant tumors.

Leoni V, Vannini A, Gatta V, Rambaldi J, Sanapo M, Barboni C, Zaghini A, Nanni P, Lollini PL, Casiraghi C, Campadelli-Fiume G.

PLoS Pathog. 2018 Aug 6;14(8):e1007209. doi: 10.1371/journal.ppat.1007209. eCollection 2018 Aug.

5.

Panniculitis in a patient with pathologic complete response to talimogene laherparepvec treatment for recurrent, in-transit melanoma.

Long TH, Shinohara MM, Argenyi ZB, Thompson JA, Gardner JM.

J Cutan Pathol. 2018 Jul 27. doi: 10.1111/cup.13332. [Epub ahead of print]

PMID:
30054925
6.

Herpes simplex virus type 1 infection promotes the growth of a subpopulation of tumor cells in 3D uveal melanoma cultures.

Valyi-Nagy T, Fredericks B, Ravindra A, Hopkins J, Shukla D, Valyi-Nagy K.

J Virol. 2018 Jul 25. pii: JVI.00700-18. doi: 10.1128/JVI.00700-18. [Epub ahead of print]

7.

Oncolytic herpes simplex virus immunovirotherapy in combination with immune checkpoint blockade to treat glioblastoma.

Saha D, Martuza RL, Rabkin SD.

Immunotherapy. 2018 Jul;10(9):779-786. doi: 10.2217/imt-2018-0009.

PMID:
30008259
8.

Personalized Cancer Vaccine Platform for Clinically Relevant Oncolytic Enveloped Viruses.

Ylösmäki E, Malorzo C, Capasso C, Honkasalo O, Fusciello M, Martins B, Ylösmäki L, Louna A, Feola S, Paavilainen H, Peltonen K, Hukkanen V, Viitala T, Cerullo V.

Mol Ther. 2018 Sep 5;26(9):2315-2325. doi: 10.1016/j.ymthe.2018.06.008. Epub 2018 Jun 19.

9.

HSV as A Platform for the Generation of Retargeted, Armed, and Reporter-Expressing Oncolytic Viruses.

Menotti L, Avitabile E, Gatta V, Malatesta P, Petrovic B, Campadelli-Fiume G.

Viruses. 2018 Jun 30;10(7). pii: E352. doi: 10.3390/v10070352.

10.

Oncolytic Virotherapy by HSV.

Watanabe D, Goshima F.

Adv Exp Med Biol. 2018;1045:63-84. doi: 10.1007/978-981-10-7230-7_4.

PMID:
29896663
11.

Stability and anti-tumor effect of oncolytic herpes simplex virus type 2.

Wang Y, Jin J, Wu Z, Hu S, Hu H, Ning Z, Li Y, Dong Y, Zou J, Mao Z, Shi X, Zheng H, Dong S, Liu F, Fang Z, Wu J, Liu B.

Oncotarget. 2018 May 15;9(37):24672-24683. doi: 10.18632/oncotarget.25122. eCollection 2018 May 15.

12.

A novel oncolytic herpes simplex virus armed with the carboxyl-terminus of murine MyD116 has enhanced anti-tumour efficacy against human breast cancer cells.

Cheng L, Jiang H, Fan J, Wang J, Hu P, Ruan Y, Liu R.

Oncol Lett. 2018 May;15(5):7046-7052. doi: 10.3892/ol.2018.8247. Epub 2018 Mar 13.

13.

A Phase I clinical trial of EUS-guided intratumoral injection of the oncolytic virus, HF10 for unresectable locally advanced pancreatic cancer.

Hirooka Y, Kasuya H, Ishikawa T, Kawashima H, Ohno E, Villalobos IB, Naoe Y, Ichinose T, Koyama N, Tanaka M, Kodera Y, Goto H.

BMC Cancer. 2018 May 25;18(1):596. doi: 10.1186/s12885-018-4453-z.

14.

RESTRICTION OF γ34.5-DELETED ONCOLYTIC HERPES SIMPLEX VIRUS REPLICATION IN GLIOBLASTOMA STEM-LIKE CELLS.

Peters C, Paget M, Tshilenge KT, Saha D, Antoszczyk S, Baars A, Frost T, Martuza RL, Wakimoto H, Rabkin SD.

J Virol. 2018 May 23. pii: JVI.00246-18. doi: 10.1128/JVI.00246-18. [Epub ahead of print]

PMID:
29793956
15.

Comparison of infectivity and spread between HSV-1 and HSV-2 based oncolytic viruses on tumor cells with different receptor expression profiles.

Fu X, Tao L, Wang PY, Cripe TP, Zhang X.

Oncotarget. 2018 Apr 20;9(30):21348-21358. doi: 10.18632/oncotarget.25096. eCollection 2018 Apr 20.

16.

The emerging role of oncolytic virus therapy against cancer.

Russell L, Peng KW.

Chin Clin Oncol. 2018 Apr;7(2):16. doi: 10.21037/cco.2018.04.04.

17.

Metastatic melanoma with diffuse melanosis histologically after stable response to talimogene laherparepvec therapy.

Rizzo JM, Fecher LA, Chan MP, Durham AB.

JAAD Case Rep. 2018 Apr 4;4(4):379-381. doi: 10.1016/j.jdcr.2018.01.023. eCollection 2018 May. No abstract available.

18.

A Novel Oncolytic Herpes Capable of Cell-Specific Transcriptional Targeting of CD133± Cancer Cells Induces Significant Tumor Regression.

Terai K, Bi D, Liu Z, Kimura K, Sanaat Z, Dolatkhah R, Soleimani M, Jones C, Bright A, Esfandyari T, Farassati F.

Stem Cells. 2018 Aug;36(8):1154-1169. doi: 10.1002/stem.2835. Epub 2018 Jul 17.

PMID:
29658163
19.

Combinatorial Effects of VEGFR Kinase Inhibitor Axitinib and Oncolytic Virotherapy in Mouse and Human Glioblastoma Stem-Like Cell Models.

Saha D, Wakimoto H, Peters CW, Antoszczyk SJ, Rabkin SD, Martuza RL.

Clin Cancer Res. 2018 Jul 15;24(14):3409-3422. doi: 10.1158/1078-0432.CCR-17-1717. Epub 2018 Mar 29.

PMID:
29599413
20.

[The therapeutic effect of HSV1-hGM-CSF combined with doxorubicin on the mouse breast cancer model].

Zhuang XF, Zhang SR, Liu BL, Wu JL, Li XQ, Gu HG, Shu Y.

Zhonghua Zhong Liu Za Zhi. 2018 Mar 23;40(3):178-185. doi: 10.3760/cma.j.issn.0253-3766.2018.03.004. Chinese.

PMID:
29575835

Supplemental Content

Loading ...
Support Center